The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here.
He bought at .58
Nice mention of Skin via ADVFN Promoting Opti this morning.
Optibiotix also has shares in Aim Listed Skinbiotherapeutics (LSE:SBTX) worth £16 million ( at a 48.5p Skin share price) . Skin has results on March 29 and we expect a very bullish update on the launch of its psoriasis product plus possibly news on the Croda (LSE:CRDA) product launch and possibly news of a big new deal in toothpaste. We reckon that shares in Skin should zoom through 100p this year and might be worth 350p in a couple of years as Tom explained HERE – that would be a clear massive bonus for Optibiotix but let’s stick with the£16 million asset for now.
Optibiotix also has cash as we speak of c£3.5 million.
And its remaining businesses generated sales last year of £1.1 million and should be at £5-8million by calendar 2023 – again yielding a PTP of as much as £3million. So even discounting back and 50% risk weighting that business should be worth £25 million today. But if you do a SOTP of the other assets you already reach a number of £41.5 million or 47.5p per share. In other words, ongoing Optibiotix is currently being valued by Mr Market at MINUS 12p per share! ( Yes – MINUS £10million!). Yet in reality even on a conservative view, a business already profitable at an operating level must be worth at least £25 million.
The maths are clear. We know that Mr Market has fallen out of love with Optibiotix and its boss Steve O’Hara but with O’Hara promising further value creating spin-offs Mr market is clearly very wrong.
Both Tom Winnifrith and Steve Moore are long term investors in Optibiotix and will not be selling their Optibiotix (and distributed Probiotix) shares for anything less than well over a quid but accept that this is long term investing. This website is about shorter term trading so:
The short term Trade: Buy at 36p and at up to 38p targeting 52p to sell within months, possibly weeks is Skinbiotherapeutics serves up something special on the 29th.
This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Plc. ADVFN Plc does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Related Articles:
Premaitha – Bits and bobs mostly good but… by Tom Winnifrith
The August share tip of the month is not Optibiotix but we were sorely tempted..instead by Tom Winnifrith
Optibiotix - share price
only 3000 subscriptions Belgrano !
Here we go I think think it will all get very interesting in the coming three months or so. Sales galore !!
I look forward to the presentation on the 26th October, hopefully we get some figures on sales etc which I personally think could be huge.
I am sure if you were a sufferer then you would pay a whole lot more than £1.20 - £2 per sachet ! Absolute bargain
Great results, but this must also put Skin as a possible take over target from one of the big boys now.
I'll guess at £1.06
My guess is the 14th May with all fingers crossed !
AA have already had many dealings with Eurasia back in 2014 so would make sense for them to be involved.